PolyPeptide Group Expands Credit Facilities

PolyPeptide Group AG, a global CDMO specializing in peptide-based pharmaceutical ingredients, has announced an expansion of its existing credit facilities. The company, with UBS as the coordinator, has secured an increase in its revolving credit facility by EUR 40 million, bringing the total to EUR 151 million. This extension pushes the facility term to March 2028, supported by a consortium including Danske Bank and Zürcher Kantonalbank.

In addition, Draupnir Holding B.V., the main shareholder, has strengthened its support through the extension of outstanding amounts under its short-term facility. This enhanced financial flexibility aims to aid PolyPeptide’s growth strategy, responding to rising customer demand, particularly in the metabolic and GLP-1 markets.